- Infusion Pumps
- Metered Dose Inhalers
- Nebulizers
- Syringes
- Ocular Inserts
- Nasal Sprays
- Implantable Drug Delivery Devices
- Transdermal Patches
- Trans-Mucosal Drug Delivery Devices
- Others
Asia Pacific Drug Delivery Devices Market size was valued at USD 228.4 million in 2022 and is poised to grow at a CAGR of 7.2% from 2023 to 2029. Drug delivery devices are used to deliver drugs or chemical substances into the body for therapeutic effects by using different formulations, technologies, and approaches. These devices can be used for diagnosis, treatment, cure, or prevention of various diseases such as diabetes, autoimmune disorders, bacterial and viral infections, and allergies among others. Various medicinal formulations such as antibiotics and insulin are most commonly administered by using these devices to increase the efficiency of the drug by controlling dosage, time, and releasing the drug at a specific site in the body.
Drivers: Increase in the prevalence of chronic diseases such as diabetes and cancerin China, India, and Japan Adoption of newer drug delivery devices and acquisitions between the market players Rise in awareness about self-injector devices and development in healthcare expenditure
Restraints: Stringent regulation for the approval of drug delivery devices Product recalls and Complications in the use of drug delivery devices such as dosage errors High cost of drug delivery devices
2023 is the base year and 2030 is the forecast year.
The report covers the Asia Pacific drug delivery devices market data: China, India, Japan, Australia and New Zealand
The Asia Pacific drug delivery devices market key players are Becton Dickinson and Company, Hoffmann La Roche Ltd., Smiths medical Inc., Braun Melsungen AG, Pfizer, Inc. (U.S.)